title: Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
abstract: PURPOSE: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy. EXPERIMENTAL DESIGN: RNA was extracted from archived tumor samples derived from 378 patients with stage I to III HR-positive, HER2-normal breast cancer and analyzed by reverse transcription-PCR for a panel of 374 genes, including the 21-gene recurrence score (RS). Patients were randomized to receive adjuvant doxorubicin plus cyclophosphamide or docetaxel in trial E2197, with no difference in recurrence seen in the treatment arms. All available recurrent cases were selected plus a nonrecurrent cohort. Cox proportional hazard models were used to identify relationships between gene expression and recurrence. RESULTS: TOP2A expression exhibited the strongest association with increased recurrence risk (P = 0.01), and was significantly associated with recurrence (P = 0.008) in a multivariate analysis adjusted for clinicopathologic features. Elevated TOP2A expression above the median was associated with a 2.6-fold increase (95% confidence interval, 1.3-5.2; P = 0.008) in risk of recurrence if the RS was <18, and a 2.0-fold increase (95% confidence interval, 1.2-3.2, P = 0.003) if there was an intermediate RS of 18 to 30. CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker. (Clin Cancer Res 2009;15(24):7693-700).
authors.affiliation: Authors' Affiliations: Eastern Cooperative Oncology Group, Brookline, Massachusetts; Sanofi-Aventis, Bridgewater, New Jersey; Genomic Health, Inc., Redwood City, California; North Central Cancer Treatment Group, Rochester, Minnesota; Cancer and Leukemia Group B, Chicago, Illinois; and Southwest Oncology Group, Ann Arbor, Michigan.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Goldstein
authors.forename: Barrett H
authors.initials: BH
authors.lastname: Childs
authors.forename: Steven
authors.initials: S
authors.lastname: Shak
authors.forename: Diana
authors.initials: D
authors.lastname: Brassard
authors.forename: Sunil
authors.initials: S
authors.lastname: Badve
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Baehner
authors.forename: Roberto
authors.initials: R
authors.lastname: Bugarini
authors.forename: Steve
authors.initials: S
authors.lastname: Rowley
authors.forename: Edith
authors.initials: E
authors.lastname: Perez
authors.forename: Lawrence N
authors.initials: LN
authors.lastname: Shulman
authors.forename: Silvana
authors.initials: S
authors.lastname: Martino
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Davidson
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
authors.forename: Robert
authors.initials: R
authors.lastname: Gray